Netramark Holdings Inc (AINMF)

[BlairWill]

Netramark Ai $AIAI $AINMF Sponsor of ALS Conference in Boston - Dr. Joe from Netramark will be speaking...

Dr. Joe will speak on cutting edge clinical trial AI/ML technology that Netrmark is implementing

Among those companies also participating

Amylyx
Sanofi
Eledon
Bristal Myers
Biogen
Eli Lilly

To recap:
Netramark is run by Josh Spiegel...
Highlights of Mr. Spiegel's Incredible Track Record Josh was the Vice President of Business Strategy at VeraSci where he leveraged his experience to provide strategic planning and oversight of commercial operations, including the launch of the Pathway Clinical platform and positioned the company for a highly successful $330M USD exit to WCG Clinical, a leader in the pharmaceutical services sector. He was previously the consulting Vice President of Finance at Prevail Therapeutics, which was later acquired by Eli Lilly. Further, he was a founding partner and Principal at Cypress Associates LLC, a New York based Investment Banking firm, where he was responsible for a broad range of transactions including mergers and acquisitions, restructurings, and equity offerings. Before co-founding Cypress, Mr. Spiegel was an Investment Banking Analyst in the technology group at CBC World Markets. He received his BA in Economics and Public Policy from Duke University and holds the Chartered Financial Analyst® designation

https://investorintel.com/technology/netramark-is-unleashing-the-power-of-artificial-intelligence-to-revolutionize-the-pharmaceutical-industry/

https://cdn.jwplayer.com/previews/JCpbGyOr

About Company

NetraMark is a company focused on being a leader in the development of Artificial Intelligence (AI) / Machine Learning (ML) solutions targeted at the Pharmaceutical industry. Its product offering uses a novel topology-based algorithm that has the ability to parse patient data sets into subsets of people that are strongly related according to several variables simultaneously.

This allows NetraMark to use a variety of ML methods, depending on the character and size of the data, to transform the data into powerfully intelligent data that activates traditional AI / ML methods. The result is that NetraMark can work with much smaller datasets and accurately segment diseases into different types, as well as accurately classify patients for sensitivity to drugs and / or efficacy of treatment.